Quality assurance program and early toxicities in the phase III BONBIS randomized trial evaluating the role of a localized radiation boost in ductal carcinoma in situ

Mastectomy and breast conserving surgery (BCS) followed by whole breast radiotherapy (WBRT) are the standard therapeutic options for patients with ductal carcinoma in situ (DCIS), although no randomized clinical trial has compared these two strategies. Adjuvant WBRT, in which 50 Gy are delivered in 25 fractions over 5 weeks after BCS, significantly increases the local control rate with low toxicity incidence [1,2]. After the European Organization for Research and Treatment of Cancer (EORTC) trial results, a radiotherapy boost is standard practice in patients with invasive breast cancer after BCS.

Source: Radiotherapy and Oncology - September 23, 2021 Category: Radiology Authors: Celine Bourgier, Didier Cowen, Florence Castan, Claire Lemanski, Sophie Gourgou, Sofia Rivera, Alain Labib, Karine Peignaux, Magali Le Blanc-Onfroy, Ahmed Benyoucef, Alice Mege, Zineb Douadi-Gaci, Severine Racadot, Igor Latorzeff, Ulrike Schick, Stephane Tags: Original Article Source Type: research